BRD3731

BRD3731 is a selective GSK3β inhibitor, with IC50s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. BRD3731 is potentail for the research of post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorders[1].

Product Specifications

CAS Number

[2056262-07-6]

UNSPSC

12352005

Target

GSK-3

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/s-brd3731.html

Purity

98.18

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1C2=C(N=C3C([C@]2(C)C4=CC=CC=C4)=C(CC(C)(C)C)NN3)CC(C)(C)C1

Molecular Formula

C24H31N3O

Molecular Weight

377.52

References & Citations

[1]Edward Scolnick, et al. Uses of paralog-selective inhibitors of gsk3 kinases. US20160375006A1.|[2]Wagner FF, et, al. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 Mar 7;10 (431) :eaam8460.